Qualsera

The Qualsera Vision: Peptides that Consumers can Trust Read more: qualsera.org/2026/03/16/the…

@TrustPointe We have SOPs in place. Every step is documented from the time it's ordered to the time it's put in stock. We keep this documented so if there's issues between our manufacturer to our own internal team we know where to find an issue.

@rorynotsorry It’s a riskier market. I think consumers should ask!

@QualseraMark I’m currently learning all about the compounding pharmacy process from an insider. This one at least does very high-quality testing. Can you imagine a scenario where they go after Gray, and the consumers start bugging the compounding pharmacies for COA’s 😂

I think there is an assumption that Compounding Pharmacies are higher quality than Gray, but I have never seen a COA or testing from one... and I know for a fact that gray market peptides get "re-purposed" to them.

@rorynotsorry But grey market consumers expect to see COAs when they buy a product, which forces providers to provide COAs with every lot

@rorynotsorry It’s one of the areas the grey market is ahead of compounded pharmacies Pharmacies are audited against their processes and their own internal testing. They don’t share their internal testing as part of selling products, just like pharma doesn’t when you buy a bottle of ibuprofen

Batch numbers are only as good as the lot identification and traceability controls behind them, and trust me, they aren’t there. In an ideal state, a single lot number would trace back to one vial batch and one mixing batch. If anything was wrong, you could recall the one lot and get all the bad product. In general (sure there are exceptions), this level of control doesn’t exist in this market, so shipments of 20mg tirz are mixed vials from multiple production lots, rendering lot numbering after meaningless. Based on the report from @QualseraMark, we have a hard enough time knowing what is in the vial (identification) 🤣

Will be interesting to see what happens as the licensed compounders (503A and 503B) start up. Still heavily regulated, with strict limitations on quantities, but state enforcement is lax. Michigan outsources pharmacy inspections to NABP and doesn’t follow up on findings .

@ChunkOfTheStars @rorynotsorry You are not wrong. They’ve been the backbone of US drug production for decades.

@rorynotsorry @QualseraMark I should probably add china is the only country that can produce peptides *at scale* before some ass hole jumps in trying to mansplain production lines to someone who automates industrial manufacturing facilities for a living.

This is a timely question because @QualseraMark just released this report on the state of peptide testing. qualsera.org/2026/03/31/202…

@ChunkOfTheStars @rorynotsorry The bulk of the Active Pharmaceutical Ingredient (API) manufacturing is in China, but from there the batch mixing, vial, filling, and lyophilization can be performed in China or here in the US. There are some vendors also synthesizing their own APIs here in the US.

@rorynotsorry @QualseraMark It's funny because as far as I know China is the only country with labs capable of producing peptides. As far as I know all peptides are from China. Even the ones compounding pharmacies use

We will evaluate 1 - 2 candidates for consideration to be Qualsera Certified this year. Candidates have to 1) own their manufacturing processes and 2) demonstrate a significant commitment to quality assurance and control. Please tag your favorite supplier so we can connect 👇🏻

RT @rorynotsorry: State of Peptide Testing This industry report on the state of peptides and peptide testing in industry by @QualseraMark…

Download the Full Report (PDF) below: qualsera.org/2026/03/31/202…

We analyzed peptide products across the market. The results were not what we expected. 🧵

Curious how people think about: • Overfilling • Label accuracy • What “quality” should mean

Not calling out companies. Just showing how the market behaves.